GLP-1 binds its receptor through a two-domain model. This process has four sequential steps: Step 1: C-terminal docking: The C-terminal alpha-helix of GLP-1 docks onto the receptor ECD.
1. The Stanford 2026 Discovery: What Was Actually Found. The April 2026 Stanford publication drew attention to a class of dietary polyphenols and short-chain fatty acids produced during fermentation that appear to bind to or sensitise GLP-1 receptor pathways in intestinal L-cells.
Wegovy and Zepbound both belong to a class of drugs that mimic a gut hormone called GLP-1. Both of these drugs bind GLP-1 receptors in the brain, which seems to reduce hunger.
Orforglipron is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor. GLP-1 is a physiological regulator of appetite and caloric intake.
GLP-1 receptor agonists mimic the action of the natural GLP-1 hormone, which is secreted in the gut in response to food intake. This hormone plays a critical role in appetite regulation and metabolic processes. Here's how
![View of Can Semaglutide Bind Tighter to GLP-1R?[v1] | Preprints.org](https://www.preprints.org/frontend/manuscript/482d59f0f300944b525be5295c72aeca/download_pub/figure/preprints-30101-grafic.png "Can Semaglutide Bind Tighter to GLP-1R?[v1] | Preprints.org")
